Axsome Therapeutics (AXSM) Leases (2020 - 2026)

Axsome Therapeutics' Leases history runs 7 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• In Q1 2026, Leases fell 16.26% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $20.0 million (down 16.26% YoY), while the FY2025 annual figure was $20.9 million, up 287.48% from the prior year.
• Leases came in at $20.0 million for Q1 2026 at Axsome Therapeutics, down from $20.9 million in the prior quarter.
• In the past five years, Leases ranged from a high of $23.9 million in Q1 2025 to a low of $106000.0 in Q1 2023.
• A 5-year average of $9.2 million and a median of $6.4 million in 2024 frame the typical range for Leases.
• Across the five-year window, Leases sank 88.8% in 2023 and surged 5948.11% in 2024, its largest moves.
• Axsome Therapeutics' Leases stood at $420000.0 in 2022, then jumped by 1512.38% to $6.8 million in 2023, then declined by 20.51% to $5.4 million in 2024, then jumped by 287.48% to $20.9 million in 2025, then slipped by 4.05% to $20.0 million in 2026.
• According to Business Quant data, Leases over the past three periods registered $20.0 million, $20.9 million, and $21.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison